-
公开(公告)号：US5264555A
公开(公告)日：1993-11-23
申请号：US913138
申请日：1992-07-14
申请人： Robert G. L. Shorr , Kwang Nho , Myung-ok P. Cho , Chyi Lee , Barbara Czuba , Hariharan Shankar
发明人： Robert G. L. Shorr , Kwang Nho , Myung-ok P. Cho , Chyi Lee , Barbara Czuba , Hariharan Shankar
IPC分类号： C07K14/805 , C07K3/02 , C07K3/12 , C07K3/22 , C07K15/06
CPC分类号： C07K14/805
摘要： Methods are disclosed for separating hemoglobin from erythrocytes by contacting erythrocytes with a hypotonic buffer solution at a rate sufficient to render the release of hemoglobin from said erythrocytes without significant lysis. The hemoglobin is then separated from the erythrocytes. Methods are also disclosed for purifying hemoglobin solutions of DNA, endotoxins and phospholipids by contacting the hemoglobin solutions with an anion exchange medium.
摘要翻译： 公开了通过使红细胞与低渗缓冲溶液接触的速率，以足以使血红蛋白从所述红细胞中释放而没有显着裂解的速率来分离血红蛋白与红细胞的方法。 然后将血红蛋白与红细胞分离。 还公开了通过使血红蛋白溶液与阴离子交换介质接触来纯化DNA，内毒素和磷脂的血红蛋白溶液的方法。
-
公开(公告)号：US5478805A
公开(公告)日：1995-12-26
申请号：US146847
申请日：1993-11-03
申请人： Robert G. L. Shorr , Myung-Ok P. Cho , Kwang Nho
发明人： Robert G. L. Shorr , Myung-Ok P. Cho , Kwang Nho
IPC分类号： A61K38/16 , A61K38/00 , A61K47/48 , A61P7/08 , C07K1/18 , C07K14/805 , C07K17/06 , C07K17/08 , C12N11/08
CPC分类号： A61K47/48215 , A61K47/48307 , C07K14/805 , C07K17/06 , A61K38/00
摘要： Hemoglobin-containing solutions containing polyalkyene oxide-conjugated hemoglobin having a molecular weight greater than about 85,000 daltons and a degree of substitution of at least five polyalkylene oxide conjugates per hemoglobin molecule are described that are not associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is also disclosed.
摘要翻译： 描述了含有分子量大于约85,000道尔顿的聚亚烷基氧化物缀合的血红蛋白和每个血红蛋白分子至少五个聚环氧烷共轭物的取代程度的含血红蛋白的溶液，其与哺乳动物的血红蛋白尿不相关。 还公开了同时分离和纯化聚环氧烷共轭血红蛋白的方法。
-
公开(公告)号：US5312808A
公开(公告)日：1994-05-17
申请号：US960007
申请日：1992-10-13
申请人： Robert G. L. Shorr , Myung-Ok P. Cho , Kwang Nho
发明人： Robert G. L. Shorr , Myung-Ok P. Cho , Kwang Nho
IPC分类号： A61K38/16 , A61K38/00 , A61K47/48 , A61P7/08 , C07K1/18 , C07K14/805 , C07K17/06 , A61K37/00 , C07K3/12
CPC分类号： A61K47/48215 , A61K47/48307 , C07K14/805 , C07K17/06 , A61K38/00
摘要： Hemoglobin-containing solutions containing polyalkylene oxide-conjugated hemoglobin having a molecular weight greater than about 85,000 daltons and a degree of substitution of at least five polyalkylene oxide conjugates per hemoglobin molecule are described that are not associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is also disclosed.
摘要翻译： 描述了含有分子量大于约85,000道尔顿的聚环氧烷共轭血红蛋白和每个血红蛋白分子至少五个聚环氧烷共轭物的取代度的含血红蛋白的溶液，其与哺乳动物的血红蛋白尿不相关。 还公开了同时分离和纯化聚环氧烷共轭血红蛋白的方法。
-
公开(公告)号：US06824782B2
公开(公告)日：2004-11-30
申请号：US09791540
申请日：2001-02-26
IPC分类号： A61K39395
CPC分类号： G01N33/6857 , A61K47/60 , A61K2039/505 , C07K16/30 , C07K19/00 , C07K2317/41 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
摘要翻译： 本发明涉及通过将聚（乙二醇）PEG和类似的聚（环氧烷）的链共价连接到具有三维折叠的单链多肽结合分子的单链多肽的化学修饰，因此涉及 抗体的可变区的结合能力和特异性。 与亲本多肽相比，修饰的单链多肽结合分子的这种制剂具有降低的免疫性和抗原性，并且在血流中具有更长的半衰期。 修饰的单链多肽结合分子的这些有益性质使得它们在各种治疗应用中非常有用。 本发明还涉及能够进行PEG化的多价抗原结合分子。 公开了用于生产聚乙二醇化抗原结合蛋白的遗传构建，使用方法和方法的组合物。
-
5.再颁专利Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells 有权含有可用于治疗靶向组织和细胞的纳米颗粒的药物和诊断组合物公开(公告)号：USRE43295E1
公开(公告)日：2012-04-03
申请号：US13090506
申请日：2011-04-20
IPC分类号： A61K9/127 , A61K31/44 , A61K31/355 , A61K31/13 , A01N43/42 , A01N43/02 , A01N43/26 , A01N33/00
摘要： Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
摘要翻译： 由选择性脂质组制成并且任选地含有治疗活性剂的纳米颗粒被用于药物组合物中用于递送至靶向组织和/或细胞用于治疗或诊断诸如癌症的疾病。
-
公开(公告)号：US5650388A
公开(公告)日：1997-07-22
申请号：US497031
申请日：1995-06-30
IPC分类号： A61K38/00 , A61K47/48 , C07K14/805 , A61K38/42 , C07K14/05
CPC分类号： A61K47/48215 , C07K14/805 , A61K38/00
摘要： Polyalkylene oxide-conjugated hemoglobin solutions having a molecular weight greater than about 85,000 daltons and a degree of substitution of which substantially avoids clinically significant nephrotoxicity associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is al so disclosed.
摘要翻译： 具有大于约85,000道尔顿分子量的聚环氧烷 - 共轭血红蛋白溶液，其取代程度基本上避免了与哺乳动物血红蛋白尿有关的临床显着的肾毒性。 聚氧化烯共轭血红蛋白的同时分级和纯化方法如此公开。
-
公开(公告)号：US08263653B2
公开(公告)日：2012-09-11
申请号：US12604763
申请日：2009-10-23
IPC分类号： A61K31/205
CPC分类号： A61K47/18 , A61K31/19 , A61K31/20 , A61K31/381 , A61K45/06 , A61K47/183 , A61K47/22 , A61K47/36 , A61K47/541 , Y02A50/409 , Y02A50/475 , Y02A50/479 , A61K2300/00
摘要： The invention provides ion pairs of a lipoic acid derivative and an ion pairing agent, pharmaceutical formulations containing such ion pairs, and methods of using the ion pairs and pharmaceutical formulations in the treatment of medical disorders, such as cancer. An exemplary ion pair is the ion pair formed by bis-benzyl lipoate and triethanolamine. The pharmaceutical formulations may comprise a dextrose solution as a diluent.
摘要翻译： 本发明提供了硫辛酸衍生物和离子配对剂的离子对，含有这种离子对的药物制剂，以及使用离子对和药物制剂治疗医学疾病如癌症的方法。 示例性离子对是由二苄基脂肪酸酯和三乙醇胺形成的离子对。 药物制剂可以包含作为稀释剂的葡萄糖溶液。
-
公开(公告)号：US07150872B2
公开(公告)日：2006-12-19
申请号：US10915069
申请日：2004-08-10
CPC分类号： G01N33/6857 , A61K47/60 , A61K2039/505 , C07K16/30 , C07K19/00 , C07K2317/41 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
-
公开(公告)号：US06872393B2
公开(公告)日：2005-03-29
申请号：US09791578
申请日：2001-02-26
IPC分类号： G01N33/53 , A61K39/38 , A61K47/48 , A61P35/00 , C07H21/04 , C07K14/00 , C07K14/715 , C07K16/00 , C07K16/30 , C07K16/44 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/84 , G01N33/68 , A61K39/395 , C07K16/46
CPC分类号： G01N33/6857 , A61K47/60 , A61K2039/505 , C07K16/30 , C07K19/00 , C07K2317/41 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
-
10.发明授权
公开(公告)号：US5527775A
公开(公告)日：1996-06-18
申请号：US323444
申请日：1994-10-13
申请人： Robert G. L. Shorr , Mike A. Clark
发明人： Robert G. L. Shorr , Mike A. Clark
CPC分类号： A61K38/1709 , C07K14/4705
摘要： Methods of treating mammalian neoplastic disease are disclosed using phospholipase A.sub.2 activating proteins and fragments thereof.
摘要翻译： 使用磷脂酶A2活化蛋白及其片段公开了治疗哺乳动物肿瘤疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.039 秒)
